 |
 |
New York (Dow Jones)-Neotherapeutics Inc.(NEOT) shares doubled in value Wednesday after the biotechnology company said limited clinical trials of its treatment for Alzheimer's disease produce memory and behavioral improvements. The company is also in pre-clinical testing of small will likely their compounds similar to AIT-082 which could combat severe dementia, depression and weight loss, Parkinson's disease, and migraines. For complete article lookup NEOT news for the daY on New York Stock Exchange.